Desipramine
Desipramine. Secondary-amine TCA — active metabolite of imipramine. Strongest NE reuptake inhibition + lowest anticholinergic burden among TCAs.… Oral half-life 21 h.
Secondary-amine TCA — active metabolite of imipramine. Strongest NE reuptake inhibition + lowest anticholinergic burden among TCAs. Used for depression + neuropathic pain when SSRIs fail.
PK: t-half 21 IS VERIFIED AND THE ARM ORDERING WAS CHECKED ADVERSARIALLY, because "21.0 versus 43.3" is exactly the ambiguous shape that produces a wrong-arm store. Two independent reads confirm the record picked correctly: the sentence asserts the half-life was LONGER with cinacalcet, so 43.3 must be the interaction arm, and the same abstract uses alone-first ordering elsewhere. Corroborated at "21.2 hr" in a separate study. The population is narrower than the record said and is now recorded: "Seventeen subjects who were genotyped as CYP2D6 EXTENSIVE METABOLIZERS were enrolled", so this does not represent poor metabolisers. F 0.5 has no source - no abstract states an absolute bioavailability for desipramine - and the nearby numbers all belong to IMIPRAMINE, whose own "absolute bioavailability was 40.2% in the control state" appears to be the origin of the imipramine record stored F. CLASS 6 APPLIES HERE IN ITS DIAGNOSABLE FORM, not as a shape guess: no human intravenous desipramine study exists, so 2300 L is necessarily V/F, and F is pinned to 1 accordingly. ka 1.5 is removed because IMIPRAMINE STORES THE IDENTICAL 1.5 - a tricyclic class default propagated across records. Desipramine concentrates in erythrocytes, and its kinetics turn non-linear above 150 micrograms/L in at least a third of people.
Pharmacokinetics
- Oral — t½ 21 h · F 100% · Vd 2300 L
Sources: PMID:3965690, PMID:2185906